BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024.
Source: fool.com
Jon Stonehouse News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jon Stonehouse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jon Stonehouse Today - Breaking & Trending Today
Why Is BioCryst Stock Trading Higher On Monday? - BioCryst Pharma (NASDAQ:BCRX)
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue
Source: benzinga.com
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023.
Source: fool.com
Hoover council OKs $1.8 million in tax breaks for BioCryst Pharmaceuticals expansion
BioCryst Pharmaceuticals plans to invest $22 million to add about 20,000 square feet of lab space at its Discovery Center of Excellence in Riverchase.
Source: hooversun.com
Durham pharma BioCryst to unveil bigger pipeline; its top product drives more sales
BioCryst Pharmaceuticals plans to introduce products for an expanding lineup of treatments today but Thursday's latest financial results points to further sales for its Orladeyo which the company says is on target to hit $1 billion in annual sales.
Source: wraltechwire.com